ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF
The disclosure features fusion proteins that are conditionally active variants of a cytokine of interest. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling. Typically, the fusion proteins further comprise an in vivo half-life extension element, which may be cleaved from the cytokine in the tumor microenvironment.
1 . A method of treating cancer in a subject comprising administering to the subject in need thereof:
a pharmaceutical composition comprising a fusion polypeptide having the formula of: [D]-[L1]-[A]-[L2′]-[H], wherein,
[A] is an interferon alpha (IFNα) polypeptide, a mutein, or an active fragment thereof;
[D] is a blocking moiety;
[H] is a half-life extension moiety;
[L1] is a protease-cleavable polypeptide linker comprising the amino acid sequence of SEQ ID NO: 609, 612, or 615; and
[L2′] is a protease-cleavable polypeptide linker comprising the amino acid sequence of SEQ ID NO: 609, 612, or 615; and
a pharmaceutically acceptable carrier,
wherein the blocking moiety and the half-life extension moiety each independently comprise human serum albumin (HSA) or an antibody or antibody fragment that binds the HSA.
2 . The method of claim 1 , wherein the IFNa polypeptide comprises a murine interferon alpha 1 (mIFNa1), murine interferon alpha 11 (mIFNa11), human interferon alpha 2b (IFNA2b), murine interferon alpha 11 (mIFNa11), interferon alpha 8 (IFNA8), interferon alpha 14 (IFNA14), interferon alpha 16 (IFNA16), or a mutein thereof.
3 . The method of claim 2 , wherein the IFNa polypeptide comprises the amino acid sequence of SEQ ID NO: 193, 548, 549 or 550.
4 . The method of claim 1 , wherein each of the blocking moiety and the half-life extension moiety comprises HSA.
5 . The method of claim 1 , wherein each of the blocking moiety and the half-life extension moiety comprises the antibody or antibody fragment that binds HSA.
6 . The method of claim 1 , wherein one of the blocking moiety and the half-life extension moiety comprises HSA and the other one of the blocking moiety and the half-life extension moiety comprises the antibody or antibody fragment that binds HSA.
7 . The method of claim 1 , wherein each of [L1] and [L2′] comprises SEQ ID NO: 609.
8 . The method of claim 1 , wherein at least one of the blocking moiety and the half-life extension moiety comprises the antibody or antibody fragment that binds HSA, and the antibody or antibody fragment has the amino acid sequence of residues 1 to 116 of SEQ ID NO: 427.
9 . The method of claim 1 , wherein the IFNα polypeptide comprises the amino acid sequence of SEQ ID NO: 193, 548, 549 or 550.
10 . The method of claim 1 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 424, 427, 539, 541, 545, 546 or 547.
11 . The method of claim 1 , wherein each of [L1] and [L2′] comprises SEQ ID NO: 612.
12 . The method of claim 11 , wherein at least one of the blocking moiety and the half-life extension moiety comprises the antibody or antibody fragment that binds HSA, and the antibody or antibody fragment has the amino acid sequence of residues 1 to 116 of SEQ ID NO: 427.
13 . The method of claim 11 , wherein the IFNa polypeptide comprises an amino acid sequence of SEQ ID NO: 193, 548, 549 or 550.
14 . The method of claim 11 , wherein the fusion polypeptide comprises the amino acid sequence selected from the group consisting of SEQ ID NO: 425, 428, 540, 542, and 551-562.
15 . The method of claim 1 , wherein each of [L1] and [L2′] comprises SEQ ID NO: 615.
16 . The method of claim 15 , wherein at least one of the blocking moiety and the half-life extension moiety comprises the antibody or antibody fragment that binds HSA, and the antibody or antibody fragment has the amino acid sequence of residues 1 to 116 of SEQ ID NO: 427.
17 . The method of claim 15 , wherein the IFNa polypeptide comprises the amino acid sequence of SEQ ID NO: 193, 548, 549 or 550.
18 . The method of claim 1 , wherein the fusion polypeptide comprises the amino acid sequence SEQ ID NO: 427, 428, or 429.
19 . The method of claim 1 , wherein the method further comprising administering to the subject a second therapeutic agent.
20 . The method of claim 19 , wherein the second therapeutic agent is an immunomodulator for treating cancer.
21 . The method of claim 19 , wherein the second therapeutic agent is a chemotherapeutic agent, radiation therapy, an immunotherapeutic agent, a T cell agonist cytokine, a CAR-T cell, an antibody-drug conjugate, or an oncolytic virus therapy.
22 . The method of claim 1 , wherein the cancer is melanoma, renal cancer, breast cancer, ovarian cancer, prostate cancer, kidney cancer, pancreatic cancer, brain cancer, bladder cancer, or lung cancer.